Approval concerns a specific finished product
FDA-approved medicines have undergone agency review for their approved uses and labeled formulations. Compounded preparations are not FDA-approved finished drugs. A prescription requirement or pharmacy license does not make these categories equivalent.[source]
This distinction is especially important in a comparison site that includes both branded access routes and compounded offers. Readers should be able to identify the category before seeing a price.
Ask why the preparation is proposed
Discuss the clinical reason for the selected preparation and the available approved alternatives with the prescriber. A lower advertised price alone does not establish that compounding is appropriate or that a product meets applicable requirements.
This publication does not make a patient-specific legal or clinical determination. It asks providers to identify the product clearly and keeps uncertainty visible.
Names and labels deserve close attention
FDA raises concerns about semaglutide salt forms, dosing errors and other problems involving unapproved GLP-1 products. Ask which form is being dispensed, which pharmacy prepares it and how to contact the pharmacist.[source]
Instructions should match the actual label and preparation. Do not reconstruct a dose from a syringe-unit example for a different concentration or another patient’s product.
Do not transfer a branded trial to a compound
SURMOUNT-5 studied specified branded weekly injections. It did not evaluate the compounded preparations reviewed on this site. Using its outcome percentages as a compounded program’s expected result would imply unverified equivalence.[source]
The same rule applies to provider rankings: a medication trial does not measure the quality of a telehealth service.
Use clearly labeled comparison groups
Compare compounded offers on their disclosed formulation, pharmacy information, care and complete cost. Compare approved products with their exact brand, dose and format visible. Then discuss the choice with the clinician rather than letting a commercial first placement or a headline price make it.
Sources & further reading
Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Each source has its own last-checked date below.
- FDA: concerns with unapproved GLP-1 drugsCompounded-product risks, salt forms, dosing errors and online red flags · Checked October 10, 2026
- Aronne et al., NEJM 2025: tirzepatide compared with semaglutide for obesityPrimary randomized trial abstract; SURMOUNT-5, 751 adults without diabetes, 72 weeks; funded by Eli Lilly · Checked October 8, 2026